Aclaris Therapeutics, Inc.
NASDAQ:ACRS · NASDAQ Global Select
+$0.03 today
Vol 4.32M · Avg 1.40M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-63.0%
avg -73.0%
ROIC
-57.7%
avg -58.1%
ROA
-40.5%
avg -52.5%
Analysis
ROA is currently the strongest return metric at -40.5% versus its period average of -52.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Neal S. Walker | Co-Founder, Chief Executive Officer & Chairman | $965,550.00 | — | 56 | $1.56M | 1.30% |
Kevin Balthaser | Chief Financial Officer | $631,710.00 | — | 39 | $188,130.00 | 0.16% |
James Loerop | Chief Business Officer | $590,160.00 | — | 61 | $198,197.00 | 0.16% |
Hugh Davis | President, Chief Operating Officer & Director | $555,541.00 | — | 66 | $56,025.00 | 0.05% |
Roland Kolbeck | Chief Scientific Officer | $492,432.00 | — | 62 | $334,900.00 | 0.28% |
Jesse W. Hall | Chief Medical Officer | $371,166.00 | — | 52 | $109,125.00 | 0.09% |
William C. Roberts | Senior Vice President of Corporate Communications & Investor Relations | — | — | 57 | $0.00 | <0.01% |
Nina Samra | Senior Vice President of Clinical Operations | — | — | — | — | — |
Matthew Rothman | General Counsel & Corporate Secretary | — | — | — | — | — |
Shaun Selness | Senior VP, Head of Discovery & Preclinical Sciences | — | — | — | — | — |
Steve Tucker | Executive Vice President of Project Leadership | — | — | — | — | — |
Meghan Dunsmore | Senior Vice President of Finance | — | — | — | — | — |
Jon Jacobsen | Senior Vice President of Chemistry | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$1.36M
Net Sentiment
$1.36M
Net selling
Most Active
Leonard Braden Michael
1 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Apr 23, 2026 | Leonard Braden Michael Indirect | Sell | 300.0K | $4.53 | $1,359,000.00 |
Analysis
Insiders reported 0 buys worth $0.00 and 1 sells worth $1.36M over the last 12 months. That adds up to net selling of $1.36M. Leonard Braden Michael was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | +38.3% (13yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Revenue at +38.3% (13yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
BioAge Labs, Inc.
NASDAQ:BIOA
$770.69M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$484.08M
Cabaletta Bio, Inc.
NASDAQ:CABA
$467.15M
908 Devices Inc.
NASDAQ:MASS
$329.17M
NeoGenomics, Inc.
NASDAQ:NEO
$283.66M
Senseonics Holdings, Inc.
NASDAQ:SENS
$272.50M
Editas Medicine, Inc.
NASDAQ:EDIT
$253.56M
Owens & Minor, Inc.
OMI
$207.07M
Exagen Inc.
NASDAQ:XGN
$105.46M
MDxHealth S.A.
MDXH
$27.94M
Who manages ACRS?
Aclaris Therapeutics, Inc. (ACRS) lists 13 active executives. The top listed executive is William C. Roberts, Senior Vice President of Corporate Communications & Investor Relations.
Are ACRS insiders buying or selling?
Recent insider activity shows net buying of $16.60M.
Explore More
Continue the stock analysis
Jump to another research area for this company.